EBV-POSITIVE LYMPHOMA
Clinical trials for EBV-POSITIVE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EBV-POSITIVE LYMPHOMA trials appear
Sign up with your email to follow new studies for EBV-POSITIVE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Matched conditions: EBV-POSITIVE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take aim at stubborn lymphoma
Disease control Recruiting nowThis early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…
Matched conditions: EBV-POSITIVE LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC